Another new FDA approval expanding the indication for Abecma. Previously, it was approved only after failure of 4 or more prior lines of therapy. However, due to showing a progression-free survival benefit 3 times that of standard regimens, it is now approved for use after only 2 lines of previous therapy.
Navigating the complexities of gene and cellular therapy can be challenging. Rely on INTERLINK’s Symphony Benefit Solutions to collaborate with you in ensuring the appropriate utilization of these high-value therapies based on evidence-based guidelines. Our expertise can help manage risks, coordinate member care, and enhance their quality of life.
